JNJ Stock Overview
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Johnson & Johnson Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$160.50 |
| 52 Week High | US$181.04 |
| 52 Week Low | US$150.11 |
| Beta | 0.54 |
| 1 Month Change | -3.46% |
| 3 Month Change | -1.91% |
| 1 Year Change | -3.73% |
| 3 Year Change | 10.19% |
| 5 Year Change | 16.16% |
| Change since IPO | 2,044.47% |
Recent News & Updates
Johnson & Johnson: The Bull Case Can No Longer Be Ignored
Sep 23Johnson & Johnson: AAA-Rated And Potentially 20% Undervalued
Sep 17Recent updates
Johnson & Johnson: The Bull Case Can No Longer Be Ignored
Sep 23Johnson & Johnson: AAA-Rated And Potentially 20% Undervalued
Sep 17Johnson & Johnson: Kenvue Separation Won't Impact Dividends
Aug 24Johnson & Johnson Stock: Outlook Amid Lawsuits
Aug 15These 4 Measures Indicate That Johnson & Johnson (NYSE:JNJ) Is Using Debt Reasonably Well
Aug 14
Future Prospects For Johnson & Johnson Following Strong Q2 Performance
Aug 07Johnson & Johnson: Resilient, But Clarification On Liability Issue Is Needed
Jul 24Johnson & Johnson Stock Q2 Earnings Preview: News On Kenvue Distribution Expected?
Jul 17Johnson & Johnson: Supplemental BLA Of Carvykti Gives Great Growth Opportunity
Jul 06Johnson & Johnson: Pay Yourself 7% With This Bond-Like Exposure
Jun 29Johnson & Johnson Relinquishes Top Spot To Eli Lilly, Shares Undervalued Amid Technical Risks
Jun 08Johnson & Johnson (NYSE:JNJ) Shares Could Be 22% Below Their Intrinsic Value Estimate
Jun 05Johnson & Johnson: The Ultimate Bull Trap Is Here
May 30Is Johnson & Johnson (NYSE:JNJ) A Risky Investment?
May 08Johnson & Johnson fails in bid to overturn $302M vaginal-mesh award – Bloomberg
Feb 21Shareholder Returns
| JNJ | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.6% | -2.5% | -3.1% |
| 1Y | -3.7% | 10.8% | 15.1% |
Return vs Industry: JNJ underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: JNJ underperformed the US Market which returned 15.1% over the past year.
Price Volatility
| JNJ volatility | |
|---|---|
| JNJ Average Weekly Movement | 2.8% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in US Market | 14.2% |
| 10% least volatile stocks in US Market | 2.5% |
Stable Share Price: JNJ is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: JNJ's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1886 | 152,700 | Joaquin Duato | https://www.jnj.com |
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Johnson & Johnson Fundamentals Summary
| JNJ fundamental statistics | |
|---|---|
| Market Cap | US$386.48b |
| Earnings (TTM) | US$13.05b |
| Revenue (TTM) | US$97.77b |
29.6x
P/E Ratio4.0x
P/S RatioIs JNJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JNJ income statement (TTM) | |
|---|---|
| Revenue | US$97.77b |
| Cost of Revenue | US$31.78b |
| Gross Profit | US$65.99b |
| Other Expenses | US$52.94b |
| Earnings | US$13.05b |
Last Reported Earnings
Jul 02, 2023
Next Earnings Date
Oct 17, 2023
| Earnings per share (EPS) | 5.42 |
| Gross Margin | 67.50% |
| Net Profit Margin | 13.35% |
| Debt/Equity Ratio | 59.7% |
How did JNJ perform over the long term?
See historical performance and comparison